Moteur de recherche d’entreprises européennes
Financement de l’UE (10,2 M €) : Initiatives de santé dans le psoriasis et le rhumatisme psoriasique ConsoRTium États européens Hor01/07/2021 Programme de recherche et d'innovation de l'UE « Horizon »
Texte
Initiatives de santé dans le psoriasis et le rhumatisme psoriasique ConsoRTium États européens
Psoriatic Arthritis (PsA) is a clinically heterogeneous disease associated with diminished quality of life. Early diagnosis is challenging and prediction of natural history or therapeutic response to treatment is suboptimal: these represent critical, contemporary unmet clinical needs. HIPPOCRATES is a multi-centre consortium, with 26 world-class partners that have clinical, scientific, data analytics, ethics, patient participation and pharmaceutical industry expertise. We will address these needs. Clinical phenotypic data from multiple established, and de novo PsA cohorts combined with a unique library of bio- samples, images, and data derived therefrom, will be curated and catalogued for optimal evaluation and use. HIPPOCRATES will analyse these multi-structured datasets that traverse the disease timeline, from cutaneous psoriasis, early PsA, first therapeutic and first biologic choice. Through machine learning and other AI techniques, we will: (1) Identify molecular signals associated with the development of PsA in patients with psoriasis, so presaging PsA prevention studies; (2) Create a diagnostic algorithm for early PsA diagnosis in patients with cutaneous psoriasis or early undifferentiated inflammatory arthritis; (3) Generate biomarker algorithms, including clinical, imaging and molecular polyomic moieties, to predict disease progression and identify endotypes permitting precision treatment with existing (methotrexate, and TNF or IL-17 inhibitor) treatments and novel therapeutic regimes; (4) Elucidate the molecular basis of PsA to facilitate future drug discovery; (5) Develop diagnostic digital tools for use in clinical settings. With highly aligned academic/clinical, SME and EFPIA partners, including involvement from existing IMI programmes and competitive international associations, HIPPOCRATES will oversee the development of a sustainable infrastructure to support PsA research and improve PsA patient outcomes.
| 675 000 € | |
| Abbvie Inc. | 0,00 € |
| 0,00 € | |
| EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GmbH | 540 750 € |
| EUROPEAN ALLIANCE OF ASSOCIATIONS FOR RHEUMATOLOGY | 83 125 € |
| FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG e. V. | 1 132 945 € |
| Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi i Sunyer | 134 375 € |
| Hospital Clinic de Barcelona | 0,00 € |
| Katholieke Universiteit Leuven | 448 400 € |
| King's College London | 100 000 € |
| Kungliga Tekniska Hoegskolan | 519 829 € |
| NOVARTIS PHARMA AG | 0,00 € |
| Neoteryx Ltd. | 0,00 € |
| Oxford Biodynamics plc | 249 375 € |
| Pfizer Ltd. | 0,00 € |
| Region Hovedstaden | 100 000 € |
| SIB SWISS INSTITUTE OF BIOINFORMATICS | 585 476 € |
| Stichting Amsterdam UMC | 130 000 € |
| 221 250 € | |
| THE European Institute for Innovation Through Health Data | 225 000 € |
| The Chancellor, Masters and Scholars of the University of Oxford | 729 686 € |
| The University of Manchester | 765 426 € |
| Trajan Scientific Europe Ltd. | 195 000 € |
| UCB Biopharma | 0,00 € |
| 501 063 € | |
| UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN | 1 492 441 € |
| Universita Cattolica Del Sacro Cuore | 130 000 € |
| University of Glasgow | 627 590 € |
| VIB VZW | 624 261 € |
https://cordis.europa.eu/project/id/101007757
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
Les visualisations de "ATTUROS Ltd. - Financement de l’UE (10,2 M €) : Initiatives de santé dans le psoriasis et le rhumatisme psoriasique ConsoRTium États européens"
sont mis à disposition par
North Data
et peuvent être réutilisées selon les termes de la licence
Creative Commons CC-BY.
